Special Lunchtime Session: The First Genome-Editing Trial (CCR5)
In this special session, some of the major contributors to the field of genome editing over the last four decades will discuss the first ever genome-editing trial which investigated a zinc finger nuclease for the prevention of HIV.
Confirmed Participants:
Dana Carroll, Ph.D., Distinguished Professor Emeritus, University of Utah School of Medicine, United States
Srinivasan Chandrasegaran, Ph.D., Professor Emeritus, Johns Hopkins School of Public Health, United States
Matthew Porteus, Prof., MD, Ph.D., Stanford Medicine, United States
More details to follow
Panel Discussion: Standards and Regulation in CRISPR Medicine
This one-hour panel discussion will focus on guidance and regulations for gene-editing therapies, lessons learned from the approval CASGEVY, international harmonisation within gene editing, and ensuring safety of gene-editing medicines for all patient groups. Audience participation is welcome.
Confirmed Panelists:
Attila Sebe, MD, PhD (Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Division of Haematology, Cell and Gene Therapy, Germany)
Dolça Rogers, Ph.D., ATMP topic lead, Pharmaceutical Quality Office, European Medicines Agency (EMA), Netherlands
Özcan Met, Ph.D., Associate Professor and Head of Cell Therapy Unit at the National Center for Cancer Immune Therapy (CCIT-DK) at Herlev University Hospital and DTU HealthTech, Denmark
Samantha Maragh, Ph.D., Leader, Genome Editing Program, National Institute of Standards & Technology (NIST), United States
More details to follow
Panel Discussion: Patient Access to CRISPR Medicine
Innovative CRISPR-based therapies hold tremendous promise for addressing a range of diseases, including rare disorders and diseases with unmet medical needs. However, ensuring equitable patient access remains a significant challenge. This one-hour panel discussion will examine key issues involved in the availability and accessibility of CRISPR-based medicines. By bringing together diverse stakeholders, the discussion aims to provide a comprehensive perspective on overcoming barriers to access and ensuring these transformative therapies reach those who need them most. Audience participation is highly encouraged.
Co-organised by Daniël Warmerdam, Ph.D., Assistant Professor, Human Genetics, UMC Amsterdam, Netherlands
Confirmed Partipicants:
Daniël Warmerdam, Ph.D., Assistant Professor, Human Genetics, UMC Amsterdam, Netherlands
Jimi Olaghere, CASGEVY recipient and patient advocate, United States
More details to follow
Special Lunchtime Session: Democratising genetic technologies
This special lunchtime session will discuss strategies to democratise genetic technologies as CRISPR/Cas9 to promote equity in research and personalised medicine approaches derived from those technologies.
More details to follow
